Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
HRTX compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
HRTX
Heron Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
HRTX
Heron Therapeutics, Inc.
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
HRTX
0 of 4
at or beyond implied
Report
implied
realized
× implied
Q2 FY26
±62.0%
▼
−31.74%
×0.51
May 11 '26
±32.7%
▼
−21.05%
×0.65
Q1 FY26
±34.8%
▲
+11.11%
×0.32
Q3 FY25
±24.3%
▼
−3.39%
×0.14
LLY
3 of 4
at or beyond implied
Report
implied
realized
× implied
Q3 FY26
±5.1%
▲
+6.63%
×1.29
Q2 FY26
±6.2%
▲
+4.86%
×0.79
= implied
HRTX realized, solid
LLY realized, hatched
One scale, both sides: full bar = 63%
× = |realized| ÷ implied
Source: market data
Q1 FY26
±5.3%
▲
+9.80%
×1.85
Feb 4 '26
±6.1%
▲
+10.33%
×1.69
HRTX
Heron Therapeutics, Inc.
Change
0.29
▲
+1.93%
Mkt cap
$53.2M
Revenue
$38M
Q2 FY26
Revenue
$155M
FY25
LLY
ELI Lilly & Co
Change
1,365.25
▲
+0.04%
Regular session
Nov 6 '26
Mkt cap
$1.2T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Regular session
Nov 6 '26
HRTX
Heron Therapeutics, Inc.
vs
LLY
ELI Lilly & Co
0.29
▲
+1.93%
Price
1,365.25
▲
+0.04%
$53.2M
Mkt cap
$1.2T
Q2 FY26
$38M
Revenue
$24.4B
Q3 FY26
FY25
$155M
Revenue
$65.2B
FY25
Change
Change
HRTX
0.29
▲
+1.93%
vs
LLY
1,365.25
▲
+0.04%
Regular session
Nov 6 '26